GSK plc

OTCPK:GLAX.F Stock Report

Market Cap: US$117.1b

GSK Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:GLAX.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Mar 26BuyUS$129,991Jonathan SymondsIndividual5,000US$26.00
20 Mar 26BuyUS$10,748Wendy Mira BeckerIndividual411US$26.15
20 Mar 26BuyUS$10,152Elizabeth AndersonIndividual196US$51.79
20 Mar 26BuyUS$165,698Gavin ScreatonIndividual6,335US$26.16
20 Mar 26BuyUS$10,152Anne BealIndividual196US$51.79
20 Mar 26BuyUS$13,458Tsun-Huei LeeIndividual195US$69.01
20 Mar 26BuyUS$10,152Harry DietzIndividual196US$51.79
20 Mar 26BuyUS$41,280Vishal SikkaIndividual797US$51.79
20 Mar 26BuyUS$79,555Charles BancroftIndividual1,536US$51.79
20 Feb 26BuyUS$99,827Wendy Mira BeckerIndividual3,334US$29.94
05 Feb 26BuyUS$71,554Jonathan SymondsIndividual2,500US$28.62
22 Dec 25BuyUS$40,180Jonathan SymondsIndividual1,650US$24.35
19 Dec 25BuyUS$10,670Wendy Mira BeckerIndividual441US$24.20
19 Sep 25BuyUS$10,655Wendy Mira BeckerIndividual526US$20.26
20 Jun 25BuyUS$26,104Jonathan SymondsIndividual1,350US$19.34
20 Jun 25BuyUS$10,538Wendy Mira BeckerIndividual545US$19.34

Insider Trading Volume

Insider Buying: GLAX.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GLAX.F?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,565,7260.0386%
Individual Insiders2,394,1130.059%
State or Government7,202,4690.177%
Private Companies48,427,6181.19%
Employee Share Scheme70,165,0271.73%
General Public450,458,11611.1%
Institutions3,478,843,76585.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 54.14% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.88%
BlackRock, Inc.
400,908,444US$11.6b13%0.14%
5.97%
Dodge & Cox
242,192,278US$7.0b-1.73%1.91%
5.36%
The Vanguard Group, Inc.
217,378,128US$6.3b0.15%0.07%
4.29%
FMR LLC
174,175,144US$5.0b16.1%0.25%
2.7%
Wellington Management Group LLP
109,561,153US$3.2b9%0.49%
2.41%
State Street Global Advisors, Inc.
97,665,039US$2.8b5.59%0.08%
2.27%
UBS Asset Management AG
92,035,009US$2.7b5.35%0.22%
1.99%
Fisher Asset Management, LLC
80,676,297US$2.3b1.32%0.77%
1.9%
Strategic Advisers LLC
77,076,348US$2.2b0.24%0.61%
1.73%
GlaxoSmithKline Employee Trust
70,165,027US$2.0b-13.9%no data
1.68%
Legal & General Investment Management Limited
68,366,604US$2.0b-4.07%0.37%
1.56%
Norges Bank Investment Management
63,413,849US$1.8b-3.53%0.12%
1.47%
Schroder Investment Management Limited
59,816,511US$1.7b18.5%0.84%
1.24%
PRIMECAP Management Company
50,260,320US$1.5b-2.47%1.07%
1.24%
Aberdeen Group Plc
50,137,169US$1.4b-4.74%0.73%
1.2%
Mondrian Investment Partners Limited
48,815,207US$1.4b-6.78%9.6%
1.03%
GlaxoSmithKline plc, Shareview Client
41,899,624US$1.2b-2.39%no data
1.02%
Amundi Asset Management SAS
41,383,711US$1.2b-28.9%0.19%
0.96%
HSBC Global Asset Management (UK) Limited
38,973,667US$1.1b-23.2%0.36%
0.75%
Hargreaves Lansdown Asset Management Ltd.
30,263,480US$873.2m-4.26%1.64%
0.71%
Royal Bank of Canada Trust Company (Bahamas) Limited
28,933,614US$834.9m-1.18%21.47%
0.71%
Independent Franchise Partners, LLP
28,750,549US$829.6m-32%3.81%
0.7%
Columbia Management Investment Advisers, LLC
28,499,440US$822.3m-5.22%0.16%
0.7%
Geode Capital Management, LLC
28,352,755US$818.1m4.32%0.04%
0.68%
Royal London Asset Management Ltd.
27,742,917US$800.5m1.77%1.04%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/12 08:17
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GSK plc is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research
James GordonBarclays